Table 1.
Monoclonal and Human Serum Antibody Binding to gp140 (A) and gp120 (B) Envelope Proteins
| (A) gp140 | |||||
|---|---|---|---|---|---|
| Source antibody/envelope priming | Antibody name/timea | UG92005 | 1007 | RW | 1035 |
| Panel 1: Mouse monoclonal antibody testing | |||||
| Mouse/UG92005 | 106-1B5 | 0.91 | >5 | >5 | >5 |
| Mouse/UG92005 | 103-15C7 | 3.25 | >5 | >5 | >5 |
| Mouse/UG92005 | 103-12A3 | 3.36 | >5 | >5 | >5 |
| Mouse/UG92005 | 103-2G12 | 0.87 | >5 | >5 | <0.05 |
| Mouse/UG92005 | 103-10C4 | <0.05 | 0.06 | <0.05 | 5 |
| Mouse/1007 | 104-9B5 | >5 | 0.9 | >5 | >5 |
| Mouse/1007 | 104-6D11 | >5 | <0.05 | >5 | >5 |
| Mouse/1007 | 104-1B2 | >5 | <0.05 | >5 | >5 |
| Mouse/1007 | 104-12D10 | >5 | <0.05 | >5 | >5 |
| Mouse/1007 | 104-10G3 | >5 | <0.05 | >5 | >5 |
| Mouse/RW | 2RW12B11 | 0.32 | >5 | <0.05 | >5 |
| Panel 2: Human serum antibody testinga | |||||
| Patient sera | HB902/9 | >100,000 | >100,000 | 17,685 | 200 |
| Patient sera | HB903/13 | >100,000 | >100,000 | 31,376 | 988 |
| Patient sera | HB904/3 | 3,410 | 4,890 | 1,808 | <100 |
| Patient sera | HB905/8 | >100,000 | >100,000 | >100,000 | <100 |
| Patient sera | HB906/15 | >100,000 | >100,000 | 16,697 | <100 |
| Patient sera | HB907/4 | >100,000 | >100,000 | 22,721 | 1,116 |
| Patient sera | HB908/2 | 1,610 | 8,500 | 1,367 | <100 |
| (B) gp120 | |||||
|---|---|---|---|---|---|
| Source antibody/envelope priming | Antibody name/timea | CM | MN | BaL | ZM53M |
| Panel 1: Mouse monoclonal antibody testing | |||||
| Mouse/CM | 119-9E1 | <0.05 | >5 | >5 | >5 |
| Mouse/MN | 120-16H6 | 0.8 | 0.5 | 0.3 | >5 |
| Mouse/MN | 120-15D2 | >5 | 0.05 | >5 | >5 |
| Panel 2: Human serum antibody testinga | |||||
| Patient sera | HB902/9 | 2,531 | 9,614 | >100,000 | 21,185 |
| Patient sera | HB903/13 | 13,736 | >100,000 | >100,000 | >100,000 |
| Patient sera | HB904/3 | <100 | 3,417 | 3,368 | 515 |
| Patient sera | HB905/8 | 653 | >100,000 | >100,000 | 12,523 |
| Patient sera | HB906/15 | 19,133 | >100,000 | 33,602 | 8,945 |
| Patient sera | HB907/4 | 6,297 | >100,000 | >100,000 | >100,000 |
| Patient sera | HB908/2 | <100 | 1,619 | 1,091 | <100 |
(A) ELISA titers are shown for mouse monoclonals (Panel 1) or human sera (Panel 2), tested against gp140 envelope proteins. Sequences were originally derived from viruses UG92005, 1007, 92RW020.5 [RW], and 1035. Sequences from UG92005, 1007, and 1035 were each shuttled through a common parent vector during cloning so that a short portion of the C-terminal region of each expressed molecule was shared.
In Panel 1, values defined the lowest antibody protein concentration (in μg) that scored positively (optical density reading 0.1 or greater) in the ELISA based on nonlinear regression analyses (GraphPad Prism). A value of “>5” indicated no detectable antibody reactivity in the ELISA with 5 μg protein. In Panel 2, values defined the highest serum dilutions that gave a positive score based on nonlinear regression analyses. A value of “ <100” indicated that there was no detectable antibody reactivity in the ELISA when sera were diluted a minimum of 1:100. Relative values were coded by different formats (bold and underline = highest reactivity; bold = high reactivity; bold italics = medium reactivity; regular = low reactivity; italics = no detectable reactivity).
(B) Method descriptions and data tabulation match those in Table 1A, but with envelope gp120 instead of gp140 proteins, used both as immunogens and antigens.
For human serum samples, the time in months between the day of serum collection and the patient's previous, self-reported negative HIV-1 test (based on a negative ELISA or Western Blot) is indicated.
ELISA, enzyme-linked immunosorbent assays.